Back to Awarded Treatment Trials


Awarded Trial: 00-133

Grant ID

00-133

Illness

Schizophrenia

Primary Drug/Intervention

Risperidone

Primary Dosage

(discharge rate)

Secondary Drug Intervention

Olanzapine

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Sheitman

Sample Size

85

Duration of Study Period for Each Subject

6.9 days (Risperidone), 7 days (Olanzapine), 10-20 days

Outcome Measurements

PANSS, duration of hospitalization (number of days to discharge), GAF, Chi Square

Results

The authors compared the efficacy of risperidone and olanzapine in hospitalized acutely psychotic patients. Eighty five patients were enrolled and duration of hospitalization was the principal outcome measurement. There was no difference between the two medications on this measure.

Publication

Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry. 2005 Dec;66(12):1564-8.

Link

http://www.ncbi.nlm.nih.gov/pubmed/16401158

PI Name

Brian Sheitman

Degree

MD

Center

Department of Psychiatry

Institution

The University of North Carolina at Chapel Hill

Address

CB # 7160

City or Town

Chapel Hill

State or Province

NC

Zip or Postal Code

27599

Country

USA

Email Address

brian.sheitman@ncmail.net